

ATTORNEY'S DOCKET NUMBER: 0157755-0257 (BHC 031001 US)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Munnes, et al.

Examiner:

Not yet assigned

Serial No:

10/561,485

Group Art Unit:

Not yet assigned

Filing Date:

December 16, 2005

Title:

Methods and Kits for Investigating Cancer

Mail Stop: Amendments Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

TRANSMITTAL LETTER

Enclosed are the following documents:

- 1. Statement under 37 C.F.R. §§ 1.56, 1.97, and 1.98 (6 pages);
- 2. Form PTO-1449 (8 pages);
- 3. Cited Art (127 references); and
- 4. Return Postcard.

If any additional fees are required to be paid or if any overpayment has been made, please charge same to Deposit Account No. 03-1721.

Respectfully submitted,

Cameron M. Luitjens, Ph.D. Registration Number: 58,674

PATENT GROUP CHOATE, HALL & STEWART, LLP Two International Place Boston, MA 02110 Tel (617) 248-5000 Fax (617) 248-4000

Dated: July /, 2006

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

July 5, 2006

Date

Signature

Vincent Montalbano

Typed or Printed Name of person signing certificate



ATTORNEY'S DOCKET NUMBER: 0157755-0257 (BHC 031001 US)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Munnes, et al.

Examiner:

Not yet assigned

Serial No:

10/561,485

Group Art Unit:

Not yet assigned

Filing Date:

December 16, 2005

Title:

Methods and Kits for Investigating Cancer

Mail Stop: Amendments Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

STATEMENT UNDER 37 C.F.R. §§ 1.56, 1.97, AND 1.98

Pursuant to the duty of disclosure under 37 C.F.R §§ 1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

Type of Statement

The present Information Disclosure Statement is:

[X] An original Information Disclosure Statement; or

[] A supplemental Information Disclosure Statement.

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop: Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria,

VA 22313-1450.

July **4**Date

Signature

Vincent Montalbano

Name of Person Signing

Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

[X]	Pursu	ant to 3	7 CFR § 1.97(b); no fee or certification is required:			
	[]	Withi	n three months of the filing date of a national application other than			
		a cont	a continued prosecution application under § 1.53(d);			
	[]	Withi	Within three months of the date of entry of the national stage as set forth			
		in § 1	.491 in an international application;			
	[X]	Befor	e the mailing of a first Office action on the merits; or			
	[]	Befor	e the mailing of a first Office action after the filing of a request for			
		contir	nued examination under § 1.114.			
[]	Pursu	ant to 3	7 CFR § 1.97(c) after the dates listed above but before the mailing			
	date o	of any o	f a final action under § 1.113, a notice of allowance under § 1.311, or			
	an ac	tion that	t otherwise closes prosecution in the application; Applicant hereby			
	eithei	.				
	[]	Certif	fies that either:			
		[]	each item of information contained in the information disclosure			
			statement was first cited in any communication from a foreign			
			patent office in a counterpart foreign application not more than			
			three months prior to the filing of the information disclosure			
			statement; or			
		[]	That no item of information contained in the information			
			disclosure statement was cited in a communication from a foreign			
			patent office in a counterpart foreign application, and, to the			
			knowledge of the person signing the certification after making			
			reasonable inquiry, no item of information contained in the Page 2 of 6			

information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement; or

	[]	Includ	es herewith the fee set forth in § 1.17(p),	
[]	Pursua	int to 37	7 CFR § 1.97(d), after the mailing date of any final action under	
	§ 1.11	3, a not	ice of allowance under § 1.311, or an action that otherwise closes	
	prosecution in the application; Applicant hereby both:			
	[] Certifies that either:			
		[]	each item of information contained in the information disclosure	
			statement was first cited in any communication from a foreign	
			patent office in a counterpart foreign application not more than	
			three months prior to the filing of the information disclosure	
			statement; or	
		[]	That no item of information contained in the information	
			disclosure statement was cited in a communication from a foreign	
			patent office in a counterpart foreign application, and, to the	
			knowledge of the person signing the certification after making	
			reasonable inquiry, no item of information contained in the	
			information disclosure statement was known to any individual	
			designated in § 1.56(c) more than three months prior to the filing	
			of the information disclosure statement; and	
	[]	Includ	les herewith the fee set forth in § 1.17(p).	

[]

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

- [X] A copy of each cited reference not indicated with an asterisk is included;
- [X] A copy of each of the references cited on the attached form PTO-1449 (modified) is enclosed, except for U.S. patents and U.S. patent application publications for which the submission requirement has been waived by the PTO in the Official Gazette Notice of August 5, 2003, for applications filed after June 30, 2003;
- [] Copies of references indicated with an asterisk on the attached form PTO-1449 are not included pursuant to 37 CFR § 1.98(d) because they were previously provided to the United States Patent Office in an Information Disclosure Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the following patent application that is relied upon in the present case for an earlier effective filing date under 35 USC § 120:

Serial Number	Filing Date	Status

[] Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the aboveidentified application:

Applicant certifies that the Information Disclosure Statement either:

- [X] Does not contain non-English language citations;
- [] Includes one or more translations of a non-English citation; or

[] Does contain non-English language citations, of which the following is a concise explanation:

Remarks

The submission of this Information Disclosure Statement should not be construed as a representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in $\S 1.56(b)$.

The submission of this Information Disclosure Statement shall not be construed as a representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 USC § 102.

It is respectfully requested that:

- 1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
- 2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application; and
- 3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

Respectfully submitted,

Dated: July /, 2006

Cameron M. Luitjens, Ph.D. Registration Number: 58,674

PATENT GROUP CHOATE, HALL & STEWART, LLP Two International Place Boston, Massachusetts 02110 Tel (617) 248-5000 Fax (617) 248-4000

Form PTO-144 (REV. 8-83)	Comme	epartment of erce and Trademark Office	Atty. Docket: 0157755-0257	In re Applic 10/561,485	ation No.
INFORMATION DISCLESSURE STATEMENT (Use several sheets if necessary)			Applicant: Munnes, et al.		
			Filing Date: December 16, 2005	Group:	
U.S. PATENT	DOCUMENTS				
Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
	4,683,195	Mullis, et al.	July 28, 1987	435	6
	4,683,202	Mullis	July 28, 1987	435	91
	4,843,155	Chomczynski	June 27, 1989	536	27
	5,223,409	Ladner, et al.	June 29, 1993	435	69.7
	5,262,311	Pardee, et al.	November 16, 1993	435	91.2
	5,283,317	Saifer, et al.	February 1, 1994	528	405
	5,498,531	Jarrell	March 12, 1996	435	91.31
	5,556,752	Lockhart, et al.	September 17, 1996	435	6
· · · · · · · · · · · · · · · · · · ·	5,565,332	Hoogenboom, et al.	October 15, 1996	435	69.1
	5,578,832	Trulson, et al.	November 26, 1996	250	458.1
	5,593,839	Hubbell, et al.	January 14, 1997	435	6
	5,599,695	Pease, et al.	February 4, 1997	435	91.1
	5,631,734	Stern, et al.	May 20, 1997	356	317
	5,641,673	Haseloff, et al.	June 24, 1997	435	325
	5,705,151	Dow, et al.	January 6, 1998	424	93.21
	5,714,331	Buchardt, et al.	February 3, 1998	435	6
	5,976,813	Beutel, et al.	November 2, 1999	435	7.1
	6,203,987	Friend, et al.	March 20, 2001	435	6
U.S. PATENT	APPLICATIONS				
Examiner's Initials:	Serial Number:	Applicant:	Filing Date:	Group:	Art Unit:
	2003-143539	Bertucci, et al.	July 31, 2003		
FOREIGN PA	TENT DOCUMENT	rs		·	
Examiner's Initials	Document No.	Country	Date	Translation Yes	No
	WO 1993/03151	WO	February 18, 1993	1 20	1.0
	WO 1994/10300	WO	May 11, 1994		
	WO 1994/13804	WO	June 23, 1994		
	WO 1995/22058	WO	August 17, 1995		

Form PTO-1449	· Comme		Atty. Docket: 0157755-0257	In re Application No. 10/561,485	
(REV. 8-83)	Patent and Trademark Office		1 1 1 1 1 1	41	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Munnes, et al.			
		Filing Date: December 16, 2005	Group:		
`	TY 0 1007/00077				
	WO 1997/02357	WO	January 23, 1997		
	WO 1997/14028	WO	April 17, 1997		
	WO 1997/27317	WO	July 31, 1997		
	WO 1997/29212	WO	August 14, 1997		
	WO 1999/12826	WO	March 18, 1999		
	EP 0 321 201	Europe	December 14, 1988		
	EP 0 721 016	Europe	October 20, 1995	<u> </u>	
	EP 0 728 520	Europe	February 8, 1996		
	EP 0 799 897	Europe	April 3, 1997		
	EP 0 785 280	Europe	November 28, 1996		
	GB 2188638				
OTHER DOCU	MENTS				
Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)				
		Detection Of Point Mut Res. 23(4): 675-682, 199		Ligase Chain Reaction (Gap	
				"Trends Biotechnol., 10:	
	Agrawal and Good Degradation," Tetr	child, "Oligodeoxynuc Cahedron Letters, 28: 35	leoside Methylphospona 39-3542, 1987.	tes: Synthesis And Enzymic	
	Altschul, et al., "O 603-616, 1986.	ptimal Sequence Align	ment Using Affine Gap	Costs," Bull. Math. Bio., 48:	
	Bartel, et al., "Elin BioTechniques, 14		ves That Arise In Using	The Two-Hybrid System,"	
	Bitter, et al., "Expr 544, 1987.	ression And Secretion V	Vectors For Yeast," Meth	nods in Enzymol., 153 : 516-	
	l .	thy, "A General Metho Sci. USA, 48: 1390-139		NA Complement To DNA,	
	Bonner, et al., "Reduction In The Rate Of DNA Reassociation By Sequence Divergence," J. Mol. Biol., 81: 123-135, 1973.			Sequence Divergence," J.	
	Broglie, et al., "Li Carboxylase Small	ght-Regulated Expressi Subunit Gene In Trans	on Of A Pea Ribulose-1, sformed Plant Cells," Sc.	5-Bisophosphate ience, 224 : 838-843, 1984.	
-	Brown, "A Brief H	listory Of Oligonucleot	ide Synthesis," Meth. M	ol. Biol., 20 : 1-17, 1993.	
		al On Support Vector M very, 2(2): 121-167, 199		ognition," Data Mining and	

Form PTO-1449	U.S. Department of Commerce	Atty. Docket: 0157755-0257	In re Application No. 10/561,485
(REV. 8-83)	Patent and Trademark Office		
INFORMATION	N DISCLOSURE STATEMENT	Applicant: Munnes, et	T
(Use several sheets if necessary)		Filing Date: December 16, 2005	Group:
	Burton, "Antibody Redesign By Chain Shu Immunoglobulin Libraries," <i>Proc. Natl. Ac</i>	offling From Random Co	
	Carell, et al., "A Novel Procedure For The Molecules," Angew. Chem. Int. Ed. Engl., 3		Containing Small Organic
	Caruthers, et al., "New Chemical Methods Symp. Ser., 7: 215-223, 1980.	For Synthesizing Polynu	icleotides," Nucl. Acids Res.
	Cech, "Self-Splicing Of Group I Introns,"	Ann. Rev. Biochem., 59 :	543-568, 1990.
	Cech, "The Chemistry Of Self-Splicing RN 1987.	NA And RNA Enzymes,"	Science, 236 : 1532-1539,
	Cho, et al., "An Unnatural Biopolymer," S	cience, 261 : 1303-1305,	1993.
	Clahsen, et al., "p53 Protein Accumulation Premenopausal Women With Node-Negati 16(2): 470-479, 1998.	-	
	Cohen, et al., "A First-Generation Physical 701, 1993.	l Map Of The Human Ge	nome," Nature, 366: 698-
	Colbere-Garapin, et al., "A New Dominant Cells," J Mol Biol., 150(1): 1-14, 1981.	t Hybrid Selective Marke	er For Higher Eukaryotic
	Cole, et al., "Human Monoclonal Antibodi	es," Mol Cell Biochem.,	62 (2): 109-20, 1984.
	Coloma and Morrison, "Design And Produ <i>Nat. Biotechnol</i> , 15 : 159-163, 1997.	action Of Novel Tetravale	ent Bispecific Antibodies,"
	Copeland and Jenkins, "Development And Of The Mouse Genome," Trends in Genetic		cular Genetic Linkage Map
	Coruzzi, et al., "Tissue-Specific And Light Encoding The Small Subunit Of Ribulose- 1680, 1984.	•	
	Cote, et al., "Generation Of Human Monoc Proc. Natl. Acad. Sci., 80: 2026-2030, 198		ve With Cellular Antigens,"
	Couture and Stinchcomb, "Anti-Gene Ther Function," <i>Trends in Genetics</i> , 12 : 510-545	* ·	mes To Inhibit Gene
	Cronin, et al., "Cystic Fibrosis Mutation D Probe Arrays," Human Mutation, 7: 244-2:	• •	n To Light-Generated DNA
	Cull, et al., "Screening For Receptor Ligan C Terminus Of The lac Repressor," Proc. A		-
	Cwirla, et al., "Peptides On Phage: A Vast Natl. Acad. Sci., 87: 6378-6382, 1990.	Library Of Peptides For	Identifying Ligands," Proc.
	Devlin, "Random Peptide Libraries: A Sou Science, 249 : 404-406, 1990.	rce Of Specific Protein I	Binding Molecules,"

Form P10-1449	Commerce	0157755-0257	10/561,485	
(REV. 8-83)	Patent and Trademark Office			
INFORMATION	N DISCLOSURE STATEMENT	Applicant: Munnes, et	al.	
	ral sheets if necessary)	Filing Date:	Group:	
`		December 16, 2005	1'	
	DeWitt, et al., "'Diversomers': An Approa Diversity," Proc. Natl. Acad. Sci. USA, 90:	6909-6913, 1993.		
	Engelhard, et al., "The Insect Tracheal Syst Autographa californica M Nuclear Polyhed 1994.			
	Erb, et al., "Recursive Deconvolution Of C Sci. USA, 91: 11422-11426, 1994.	ombinatorial Chemical I	Libraries," Proc. Natl. Acad.	
	Felici, "Selection Of Antibody Ligands Fro A Multivalent Exposition Vector," J. Mol.			
	Findeis, et al., "Targeted Delivery Of DNA Biotechnol., 11: 202-205, 1993.	For Gene Therapy Via	Receptors," Trends in	
	Fodor, "Multiplexed Biochemical Assays V	Vith Biological Chips," /	Nature, 364 : 555-556, 1993.	
	Foekens, et al., "Prognostic Significance O Cancer," J. of Clinical Oncology, 16(3): 10		Primary Human Breast	
	Gallop, et al., "Applications Of Combinato Background and Peptide Combinatorial Lib	torial Technologies To Drug Discovery. 1. Libraries," J. Med. Chem., 37: 1233-1251, 1994.		
	Gasparini, et al., "Expression Of bcl-2 Prot Operable Node-Positive Breast Cancer," Ca		•	
	Guatelli, et al., "Isothermal, in vitro Amplia Reaction Modeled After Retroviral Replica 1990.		•	
	Hartman and Mulligan, "Two Dominant-ac In Mammalian Cells," <i>Proc. Natl. Acad. Sc.</i>	•	For Gene Transfer Studies	
	Haseloff, et al., "Simple RNA Enzymes Wind Activities," Nature, 334: 585-591, 1988.	ith New And Highly Spe	cific Endoribonuclease	
	Hedrick, et al., "Isolation Of cDNA Clones Proteins," Nature, 308: 149-153, 1984.	Encoding T Cell-Specif	ic Membrane-Associated	
	Henikoff and Henikoff, "Amino Acid Subs Acad. Sci. USA, 89: 10915-10919, 1992.	titution Matrices From P	rotein Blocks," Proc. Natl.	
Horn, et al., "Synthesis Of Oligonucle Strategy To The Synthesis Of 22 Oligo Polypeptide (GIP)," Nucl. Acids Res. S		kynucleotides Coding Fo	<u> </u>	
	Houghten, et al., "The Use Of Synthetic Pe Of Bioactive Peptides," BioTechniques, 13:	-	raries For The Identification	
	Iwabuchi, et al., "Use Of The Two-Hybrid Oligomerization," Oncogene, 8: 1693-1696	-	Domain Of p53 Involved In	
	Jayawickreme, et al., "Creation And Functi	_	ılti-Use Peptide Library,"	

Form PTO-1449	U.S. Department of	Atty. Docket:	In re Application No.	
(REV. 8-83)	· Commerce Patent and Trademark Office	0157755-0257	10/561,485	
(112 77 0 00)	T WOME WILL TRUMPING STATES	Applicant: Munnes, et al.		
(Use several sheets if necessary)		Filing Date: December 16, 2005	Group:	
	Kohler, et al., "Continuous Cultures Of Fus Specificity," Nature, 256: 495-497, 1975.	sed Cells Secreting Antil	oody Of Predefined	
	Kopp, et al., "Predictive Relevance Of Solution To Second Line Hormone- Or Chemothera Anticancer Research, 21: 2995-3000, 2001	py In Patients With Meta		
	Kozbor, et al., "Specific Immunoglobulin I Ascites Growth Of Human Hybridomas,"			
	Kroll, et al., "A Multifunctional Prokaryoti Affinity Purification, And Selective Detect			
	Kwoh, et al., "Transcription-based Amplift Immunodeficiency Virus Type 1 With A B Natl. Acad. Sci. USA, 86: 1173-1177, 1989	ead-Based Sandwich Hy		
		t Amplification Of DNA Fragments Adjacent To A IA," PCR Methods Applic., 1: 111-119, 1991.		
	Lam, "Application Of Combinatorial Libra Discovery," Anticancer Drug Des., 12: 145	ary Methods In Cancer Research And Drug 5-167, 1997.		
	Lam, "A New Type Of Synthetic Peptide I Nature, 354: 82-84, 1991.	Library For Identifying L	igand-Binding Activity,"	
	Landegran, et al., "A Ligase-mediated Gen 1988.	ene Detection Technique," Science, 241: 1077-1080,		
	Lee, et al., "Leukotriene E4-induced Airwa Smooth Muscle To Histamine And Eviden Receptors," Proc. Natl. Acad. Sci. USA, 81	ce For Three Separate St	-	
	Lizardi, et al., "Exponential Amplification Technology, 6: 1197-1202, 1988.	Of Recombinant-RNA I	Hybridization Probes," Bio/	
	Logan and Shenk, "Adenovirus Tripartite I Late After Infection," Proc. Natl. Acad. Sc	-	es Translation Of mRNAs	
	Lowy, et al., "Isolation Of Transforming D 817-823, 1980.	NA: Cloning The Hams	ter Aprt Gene," Cell, 22:	
	Maddox, et al., "Elevated Serum Levels In Immunochemically Similar To Eosinophil 1211-1226, 1983.	9		
	Madura, et al., "N-Recognin/Ubc2 Interact 268 : 12046-12054, 1993.	tions In The N-end Rule	Pathway," J. Biol. Chem.,	
	Mallender and Voss, "Construction, Expre chain Antibody," J. Biol. Chem., 269: 199-	•	A Bivalent Bispecific Single-	
	McConnell, et al., "The Cytosensor Microp Technology," Science, 257: 1906-1912, 19		Applications Of Silicon	

Form PTO-1449	U.S. Department of Commerce	Atty. Docket: 0157755-0257	In re Application No. 10/561,485	
(REV. 8-83)	Patent and Trademark Office	0137733 0237	10/301,103	
INFORMATION F	NICCI OCUDE CTATEMENT	Applicant: Munnes, et al.		
(Use several sheets if necessary)		Filing Date: December 16, 2005	Group:	
	Merrifield, "Solid Phase Peptide Synthesis. oc., 85: 2149-2154, 1963.	I. The Synthesis Of A	Tetrapeptide," J. Am. Chem.	
Morrison, et al., "Chimeric Human Anti With Human Constant Region Domains,		dy Molecules: Mouse A. Proc. Natl. Acad. Sci., 81	ntigen-binding Domains 1: 6851-6855, 1984.	
I	Munster, et al., "Predictive Factor For The treast Cancer," Breast Cancer Res., 3(6): 3	_	Therapy With Emphasis In	
	Muss, et al., "c-erB-2 Expression And Respositive Early Breast Cancer," New England	•	<u> </u>	
	Jakazawa, <i>et al.</i> , "UV And Skin Cancer: Siologically Relevant Exposure Measurem			
P.	leedleman and Wunsch, "A General Methamino Acid Sequence Of Two Proteins," J			
	leuberger, <i>et al.</i> , "Recombinant Antibodie 12 : 604-608, 1984.	s Possessing Novel Effe	ector Functions," Nature,	
•	Vicholls, et al., "An Improved Method For Iybridomas," J. Immunol. Meth., 165: 81-9	- -	n Antibodies From	
	Orlandi, et al., "Cloning Immunoglobulin Volymerase Chain Reaction," Proc. Natl. A	Variable Domains For Expression By The Acad. Sci., 86: 3833-3837, 1989.		
	earson, et al., "Rapid And Sensitive Sequence Sequence 183: 63-98, 1990.	ence Comparison With	FASTP And FASTA," Meth.	
	Pearson and Lipman, "Improved Tools For Biological Sequence Comparison," <i>Proc. Natl. Acad. Sci. USA</i> , 85 : 2444-2448, 1988.			
	Perez, "Current Management of Metastatic Breast Cancer," Semin. Oncol., 26(suppl.12): 1-10, 1999.			
	Porath, et al., "Immobilized Metal Ion Affinity Chromatography," Prot. Exp. Purif. 3: 263-281, 1992.			
n	remzl, et al., "Intracellular And ExtracellueoT Cells Through Reconstituted Extracel 83(2): 206-214, 2003.	-		
	Chodes, et al., "Transformation Of Maize I Biol., 55 : 121-131, 1995.	By Electroporation Of E	mbryos," Methods Mol.	
	Roberge, et al., "A Strategy For A Converge olid Support," Science, 269: 202-207, 199	•	ked Glycopeptides On A	
C	aleh, et al., "Effects Of Combined In Vivo Carcinoma In Wistar Rats Using Vitamin E Placenta," J. of Experimental Ther. & Onco	E And Cysteine Peptidas	e Inhibitors From Human	
•	almon, et al., "High-volume Cellular Scre Chemical Libraries: A New Methodology,"	_	~	

Form PTO-1449	U.S. Department of Commerce	Atty. Docket: 0157755-0257	In re Application No. 10/561,485	
(REV. 8-83)	Patent and Trademark Office			
INFORMATION I	DICCI OCUDE CTATEMENT	Applicant: Munnes, et al.		
(Use several sheets if necessary)		Filing Date: December 16, 2005	Group:	
l A	Sarkar, et al., "Restriction-site PCR: A Dir Adjacent To A Known Locus By Using Un 993.	rect Method Of Unknow niversal Primers," PCR M	n Sequence Retrieval Methods Applic., 2: 318-322,	
	Scharf, et al., "Heat Stress Promoters And 20: 125-162, 1994.	Transcription Factors,"	Results Probl. Cell Differ.,	
S	Scorilas, et al., "Determination Of Catheps nformation For Ovarian Cancer Patients,"	in B Expression May Of Biological Chem., 383 :	ffer Additional Prognostic 1297-1303, 2002.	
	Scott and Smith, "Searching For Peptide Li 390, 1990.	igands With An Epitope	Library," Science, 249: 386-	
	Sellers, "On The Theory And Computation 26: 787-793, 1974.	Of Evolutionary Distan	ces," SIAM J. Appl. Math.,	
ı	Sjolander and Urbaniczky, "Integrated Flui Analysis," <i>Anal. Chem.</i> , 63 : 2338-2345, 19		Biomolecular Interaction	
S	Sonveaux, "Protecting Groups In Oligonuc	nucleotide Synthesis," Meth. Mol. Biol. 26: 1-71, 1994.		
	Sorlie, et al., "Gene Expression Patterns Owns With Clinical Implications," Proc Natl Acc	f Breast Carcinomas Distinguish Tumor Subclasses ad Sci USA, 98(19): 10869-74, 2001.		
1	Szabo, et al., "Surface Plasmon Resonance BIA)," Curr. Opin. Struct. Biol., 5: 699-70	loramphenicol Acetyltransferase Gene In Tobacco		
	Takamatsu, "Expression Of Bacterial Chlo Plants Mediated By TMV-RNA," EMBO J			
		nimaeric Processed Immunoglobulin Genes Containing ant Region Sequences," <i>Nature</i> , 314 : 452-454, 1985.		
	redder, et al., "Isolation And Structure Of Antigen Of Human B Lymphocytes," <i>Proc</i>			
· · · · · · · · · · · · · · · · · · ·	Thirion, et al., "Mono- And Bispecific Sin Eur. J. Cancer Prev., 5: 507-511, 1996.	gle-chain Antibody Frag	ments For Cancer Therapy,"	
	Triglia, et al., "A Procedure For In Vitro A The Boundaries Of Known Sequences," Na	-	-	
	Uhlmann, et al., "Antisense Oligonucleotic 543-584, 1990.	des: A New Therapeutic	Principle," Chem. Rev., 90:	
•	Van Heeke and Schuster, "Expression Of I. Biol. Chem., 264: 5503-5509, 1989.	Human Asparagine Synt	hetase In Escherichia coli,"	
	van't Veer, et al., "Gene Expression Profil Nature, 415(6871): 530-6, 2002.	ing Predicts Clinical Ou	tcome Of Breast Cancer,"	
	Verhaar, <i>et al.</i> , "A Single Chain Fv Derive Fumour Targeting Advantages Over One I 497-501, 1995.		-	

Form PTO-1449	U.S. Department of 'Commerce	Atty. Docket: 0157755-0257	In re Application No. 10/561,485	
(REV. 8-83)	Patent and Trademark Office	0157755-0257	10/301,483	
		Applicant: Munnes, et	al.	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Filing Date: December 16, 2005	Group:	
	Wigler, et al., "Transfer Of Purified Herper Cells," Cell, 11: 223-232, 1977.	s Virus Thymidine Kinas	se Gene To Cultured Mouse	
	Wigler, et al., "Transformation Of Mamma Gene," Proc. Natl. Acad. Sci., 77: 3567-35	_	olifiable Dominant-acting	
	Winter, et al., "Man-made Antibodies," Na			
	Winter and Sinibaldi, "The Expression Of Plant Development," Results Probl. Cell D	Heat Shock Protein And Cognate Genes During Differ., 17: 85-105, 1991.		
	Wu and Wu, "Receptor-mediated Gene De 14621-14624, 1988.	livery And Expression I	n Vivo," J. Biol. Chem., 263:	
	Wu, et al., "Receptor-mediated Gene Deliving 1991.	Into A Ligand-based DNA Carrier System Results In y And Enhances Targeted Gene Expression," J. Biol.		
	Wu, et al., "Incorporation Of Adenovirus I Retention Of Original Receptor Specificity Chem., 269: 11542-11546, 1994.			
	Yan, et al., "Cathepsin B And Human Tun 123, 1998.	nor Progression," Biolog	ical Chemistry, 379 (2): 113-	
Zenke, et al., "Receptor-mediated Endocytosis Of Transferrin-Polycation Conju Efficient Way To Introduce DNA Into Hematoppietic Cells," Proc. Natl. Acad. 3655-3659, 1990.				
	Zervos, et al., "Mxi1, A Protein That Specifically Interacts With Max To Bind Myc-N Recognition Sites," Cell, 72: 223-232, 1993.			
	Zuckermann, et al., "Discovery Of Nanom Coupled Receptors From A Diverse N-(Su 37: 2678-2685, 1994.	olar Ligands For 7-Tran bstituted)glycine Peptoio	smembrane G-Protein-d Library," <i>J. Med. Chem.</i> ,	
EXAMINER	DATE CONSIDERED			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.